Making the DARPin® Difference Reality for Patients

Patrick Amstutz, CEO
Andreas Emmenegger, CFO
Michael Stumpp, COO

Presentation of the FY 2018 Results
February 7, 2019 – Molecular Partners AG (SIX: MOLN)

MOLECULAR partners

Disclaimer

This presentation is not an offer to sell or a solicitation of offers to purchase or subscribe for shares of Molecular Partners AG, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision. This presentation is not an offering circular within the meaning of Article 652a of the Swiss Code of Obligations, nor is it a listing prospectus as defined in the listing rules of the SIX Swiss Exchange AG or a prospectus under any other applicable laws. Copies of this presentation may not be sent to countries, or distributed in or sent from countries, in which this is barred or prohibited by law. This document is not a prospectus or a prospectus equivalent document and investors should not subscribe for or purchase any securities referred to in this document. This document does not constitute a recommendation regarding the shares.

This presentation contains specific forward-looking statements, beliefs or opinions, including statements with respect to the product pipelines, potential benefits of product candidates and objectives, estimated market sizes and opportunities as well as the milestone potential under existing collaboration agreements, which are based on current beliefs, expectations and projections about future events, e.g. statements including terms like “potential”, “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Molecular Partners AG and investments and those explicitly or implicitly presumed in these statements. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these statements and forecasts. Past performance of Molecular Partners AG cannot be relied on as a guide to future performance. Forward-looking statements speak only as of the date of this presentation and Molecular Partners AG, its directors, officers, employees, agents, counsel and advisers expressly disclaim any obligations or undertaking to release any update of, or revisions to, any forward looking statements in this presentation. No statement in this document or any related materials or given at this presentation is intended as a profit forecast or a profit estimate and no statement in this document or any related materials or given at this presentation should be interpreted to mean that earnings per share for the current or future financial periods would necessarily match or exceed historical published earnings per share. As a result, you are cautioned not to place any undue reliance on such forward-looking statements.

Unless stated otherwise the information provided in this presentation are based on company information. This presentation is intended to provide a general overview of Molecular Partners AG’s business and does not purport to deal with all aspects and details regarding Molecular Partners AG. Accordingly, neither Molecular Partners AG nor any of its directors, officers, employees, agents, counsel or advisers nor any other person makes any representation or warranty, express or implied, as to, and accordingly no reliance should be placed on, the accuracy or completeness of the information contained in the presentation or of the views given or implied. Neither Molecular Partners AG nor any of its directors, officers, employees, agents, counsel or advisers nor any other person shall have any liability whatsoever for any errors or omissions or any loss howsoever arising, directly or indirectly, from any use of this information or its contents or otherwise arising in connection therewith.

The material contained in this presentation reflects current legislation and the business and financial affairs of Molecular Partners AG which are subject to change and audit.

Agenda

- Review & Highlights FY 2018 — Patrick Amstutz, CEO
- Financial Results FY 2018 — Andreas Emmenegger, CFO
- Outlook 2019 & Beyond — Patrick Amstutz, CEO
- Q&A

MOLECULAR partners

Review & Highlights FY 2018

Molecular Partners:
A Swiss Biotech developing innovative protein drugs



DARPin® ENGINE

DARPin® platform as source of mono/multi-specific protein drugs
Rapid cycle of innovation to test novel therapeutic design
Validation in >1.8k patients treated to date (mainly Abicipar)

DARPin® PIPELINE

Abicipar: Phase 3 in wet AMD
MP0250: Phase 2 in MM and NSCLC
MP0274: Phase 1 in Her2 positive cancer indications
MP0310: First-in-human in multiple cancer indications in 2019

TEAM WORK

130 co-workers – purpose driven, evolutionary organization
Partnership with Allergan on Abicipar, ophthalmology assets
New partnership with Amgen on MP0310

$

CAPITAL

Multiple near-term catalysts with significant value creation potential
Well financed: on-track to steady income with Abicipar launch (2020e)

MOLECULAR partners

R&D Highlights 2018 - Oncology

- **MP0250 in MM:**
  - Phase 2 (MP0250 & Velcade® (PI)) has recruited 20 patients – activity pattern confirmed
  - Ongoing trial to be amended to focus on patients directly coming from PI backbone
  - New Phase 2 trial of MP0250 in combination with Pomalyst® (IMiD) in preparation
- **MP0250 in EGFR-mut NSCLC:**
  - Initial cohort recruitment ongoing, to date no new safety signals identified
- **MP0274 in HER2-positive tumors:**
  - First cohort completed
- **MP0310 (FAP x 4-1BB)**
  - Strategic collaboration with Amgen for clinical development, commercialization of MP0310
  - Important validation of immuno-oncology toolbox and DARPin® platform
  - First-in-human trial planned for H2 2019

R&D Highlights 2018 - Ophthalmology

- **Abicipar by Allergan:**
  - Positive phase 3 topline data on abicipar, demonstrating non-inferiority in 12-week fixed dosing regimen with <50% injections vs. Lucentis®
  - Phase 3 secondary endpoint data underline potential to become first fixed 12 week anti-VEGF for nAMD
  - Abicipar inflammation rate was 15% in phase 3 trials; further optimized formulation is being tested (MAPLE trial)
  - Allergan expects
    - to file Abicipar with the FDA in H1 2019 and market launch in 2020 in nAMD
    - results from MAPLE trial in H1 2019
    - to start Phase 3 studies in DME (diabetic macular edema) in 2019

Financial & Team Highlights FY 2018

- Strong financial position with CHF 99.0 million in cash as of December 31, 2018
- USD 50 million upfront payment from collaboration agreement with Amgen collected in January 2019
- Company funded into H2 2020, beyond Allergan's expected abicipar launch resulting in steady income stream
- Net cash used in operating activities of CHF 42.5 million in 2018, reflecting further build-out of R&D and clinical pipeline
- Operating loss of CHF 37.4 million and net loss of CHF 37.0 million in 2018
- Talent base with 118 FTE (+10% y-o-y), reflecting further build-out of oncology expertise

Highlights: Pipeline & DARPin® Product Candidates

A Balanced and Robust Portfolio



AMD: age-related macular degeneration; DME: diabetic macular edema; NSCLC: non-small cell lung cancer

MOLECULAR partners

MP0250: Reverting Adaptive Resistance



- Medical Need: Some tumors develop adaptive resistance to SOC by up-regulating VEGF and HGF
- MoA: MP0250 inhibits both VEGF and HGF simultaneously

  Blocking these adaptive escape pathways may restore clinical sensitivity to SOC
- Status: Phase 2 in MM and EGFR-mut NSCLC

Upregulation of escape pathways after SOC



Medical need: Agents that block escape pathways to SOC



SOC, standard of care; HSA, human serum albumin.

Unmet Medical Need in Multiple Myeloma (MM)

Illustrative course of disease of a MM patient[1]



our «initial» trial

MM remains incurable for most patients as cells acquire adaptive resistance to currently available therapies

- Relapse inevitable
- Time to relapse shortens with every treatment cycle
- Quality of response tends to diminish

1) Hajek, R. Strategies for the Treatment of Multiple Myeloma in 2013: Moving Toward the Cure. In “Multiple Myeloma: A Quick Reflection on the Fast Progress” (2013).

MOLECULAR partners

MP0250 Phase 2 Study in MM: Promising Signs of Efficacy



- Patient population: Patients with MM with ≥ 2 prior lines of treatment, including IMiD and PI, and no response or early relapse
- Treatment regimen: Velcade®/Dexamethasone plus MP0250
- 5 of 8 patients with objective responses (cohort 1)
- 3 of 4 patients coming directly from a PI-based regimen responded (*) (cohort 1)
- Durable remission observed in heavily pretreated patients
- MP0250 (8mg/kg) combined with Velcade® has shown tolerable safety profile
- Study ongoing with additional patients (■)

Data cut-off: 31 January 2019. dose level: 8mg/kg/3weeks.

MOLECULAR partners

MP0250 Positioning in MM and Our «planned» Trials

Multiple myeloma:
2nd most common blood cancer

Global market value of MM treatment:
$13 billion

expected to exceed
$20 billion by 2022

(CAGR: 13%)[1]



MP0250 has the potential to become backbone for later lines of treatment

our «planned» trials

1. Including US/5EU/JP. Datamonitor, August 2018.

Unique Potential of MP0250 in EGFR-mut NSCLC



Global market value (EGFR NSCLC):
ca. $2.8 billion

expected to exceed
$3.5 billion by 2023 (CAGR: 5%)[1]

No targeted drug approved after patients progress under Tagrisso® treatment

1. Including actively treated, Stage IIIb and Stage IV prevalent cases in US/5EU/JP. Datamonitor, August 2018; Tang et al Oncotarget 2016: Activating EGFR mutations are found in ~40% (Asia), ~20% (US), and ~15% (EU)

MOLECULAR partners

MP0250 in EGFR-mut NSCLC Summary

- No targeted drug approved for patients progressing on Tagrisso® treatment
- Patients with EGFR-mut NSCLC who have failed to respond to Tagrisso®
- Treatment regimen: Tagrisso® plus MP0250
- Phase 2 trial in the US
  - Recruitment of initial cohort ongoing
  - To date no new safety signals identified

MP0274: Killing HER2+ Cells by New MoA





Apoptosis:
Tumor cell suicide





MOLECULAR partners

MP0274 in HER2+ Patients Summary

- Despite good antibody-based HER2+ treatments, eventually patients progress
- Novel mode of action: MP0274 is an allosteric inhibitor blocking HER2- and HER3 signaling and inducing apoptosis
- Dose escalation of Phase 1 trial in HER2 positive tumor patients that have progressed on SOC
- Phase 1 trial in Europe:
  - Recruitment of first cohort completed

MOLECULAR partners

Immuno-Oncology MP0310 & Amgen Collaboration

Our Vision to Expand the Therapeutic Window Through Tumor-Localized Immune Modulation

Current IO therapeutics that activate the immune system (agonists) throughout the body show systemic side effects that can limit the effective dosing





Tumor-localized IO therapeutics that activate immune cells preferentially within the tumor may both increase efficacy and reduce systemic toxicities





MOLECULAR partners

MP0310 (FAP x 4-1BB): Activating T-cells in the Tumor

	Immune modulator		Localizer		Half-life extender
MP0310 DARPin® modules		+		+	
Illustrative graphic	4-1BB DARPin®		FAP DARPin®		HSA DARPin®

- Medical need: most current 4-1BB agonists activate T-cells and NK cells systemically and are limited by side-effects
- MoA: MP0310 uses binding to FAP – a tumor stromal target – to cluster and activate T-cells primarily in the tumor
- Status: MP0310 is in preclinical development and partnered with Amgen. Phase 1 to start in H2 2019



HSA, human serum albumin.

MOLECULAR partners

Strategic Collaboration with Amgen to Develop MP0310

- Collaboration Structure:
  - Collaboration and license agreement for development of MP0310 molecule (FAP x 4-1BB)
  - Co-funding of clinical development:
    - Parties will share costs in defined % for the first 3 indications subject to certain conditions
    - For all additional clinical trials, Amgen will take over all development costs
    - MP retains rights to develop and commercialize its own pipeline products in combination with MP0310
- Financials:
  - USD 50mio upfront payment
  - USD 497mio in clinical, regulatory and commercial milestones
  - Double digit, tiered royalties up to the high teens

DARPin® Toolbox: Tumor-Localized Immune Modulators

Tumor-localized immune modulators – overcoming the limitation of systemic side effects



Localizer	Immune Modulator: OX-40	4-1BB	CD40	Other Targets
Solid Tumor TAA*		TAA x 4-1BB		
Tumor Stromal Antigen		FAP x 4-1BB MP0310	FAP x CD40	
Hematologic TAA	TAA x OX40	TAA x 4-1BB	TAA x CD40	

*Tumor-Associated Antigen (TAA)

MOLECULAR partners

Ophthalmology Abicipar

Abicipar has Potential to be First Fixed 12 Week anti-VEGF



- Medical Need: current anti-VEGFs in nAMD are mostly dosed monthly or extended to bi-monthly, leading to high patient burden and under-dosing in real-world settings
- MoA: Abicipar is the only long-acting anti-VEGF and has shown to be the first fixed 12-week nAMD drug, lowering patient burden given full effectiveness in real world setting
- Status: Allergan plans FDA filing in H1 2019 and launch in 2020 and plans to start DME Phase 3 in H2 2019

Choroidal Neovascularization



OCT in nAMD

VA defect in nAMD

Source: Allergan presentation, 06 Dec 2018, VA visual acuity, OCT optical coherence tomography

Phase 3 Efficacy Results (SEQUOIA study, 1yr data)



Primary Endpoint: STABLE VISION Abicipar Q8 and Q12 Non-Inferior to Ranibizumab Q4



Secondary Endpoint: Change in BCVA From Baseline Abicipar Q8 and Q12 in SEQUOIA Non-Inferior to Ranibizumab



Secondary Endpoint: Change in CRT similar across in all groups

Source: Allergan July, 2018 and October 2018

MOLECULAR partners

Outlook: Abicipar on track for Allergan's expected 2020 launch

- Primary and secondary endpoints support abicipar potential to become the first fixed 12-week anti VEGF in nAMD

- Overall safety events between abicipar and ranibizumab were comparable
  - Intraocular inflammation potential was higher for Abicipar (15%) vs ranibizumab (< 1%)
  - Majority of inflammation was mild to moderate and were treated with topical corticosteroids

- Further optimized Abicipar material was produced and is currently being tested in clinical trial (MAPLE) – Allergan expects results in H1 2019

Key Messages from 2018

- **Clinical oncology trials all continuing with promising initial results**:
  - **MP0250** (Phase 2) demonstrated **initial activity in MM** and is **progressing in NSCLC**
    - Additional IMiD- trial in preparation in MM;
    - manufacturing of phase 3 material started
  - **MP0274** (Phase 1) ongoing in Her2+ cancers; first cohort completed
- **Strategic Collaboration with Amgen further validates DARPin® platform in IO:**
  - MP0310 slated for FIH in 2019, research ongoing to select next candidate for development
- **Oncology research** focused on differentiated DARPin applications ongoing
- **Abicipar Phase 3 in nAMD progressing with Allergan:**
  - Efficacy data underline potential to become **first fixed 12-week anti VEGF in nAMD**
  - Further optimized formulation is being tested (**MAPLE trial**)

DARPin® is a registered trademark owned by Molecular Partners AG.

MOLECULAR partners

Financial Results FY 2018

Key Figures FY2018

(CHF million, except per share and FTE data)	***FY 2018***	*FY 2017*	***change***
Revenues	**10.4**	20.0	**(9.6)**
Total expenses[1]	**(47.8)**	(45.9)	**(2.0)**
Operating result – EBIT	**(37.4)**	(25.8)	**(11.6)**
Net financial result	**0.4**	0.4	**0.0**
Net result	**(37.0)**	(25.4)	**(11.6)**
Basic net result per share (in CHF)	**(1.75)**	(1.22)	**(0.53)**
Net cash used in operations	**(42.5)**	(40.0)	**(2.5)**
Cash balance (incl. time deposits) as of Dec 31	**99.0**	141.1[2]	**(42.1)**
Number of FTE's as of Dec 31	**117.7**	107.8	**9.9**

[1] Thereof non-cash costs of CHF 5.3mn in in FY2018 and CHF 5.0mn in FY2017
[2] Including CHF 9.8m short-term time deposits
Note: Rounding differences may occur

MOLECULAR partners

EBIT De-composition

EBIT de-composition per function (CHF million)



Note: Rounding differences may occur

Balance Sheet

CHF million, as of Dec 31, 2018



Highlights

- Continuing strong balance sheet
- CHF 99.0 million cash balance, 64% of total assets
- Amgen Receivable was paid in January 2019, increasing cash balance to 96% of total assets
- Amgen contract liability (deferred revenues) of CHF 48.7 million to be recognized as revenues in 2019 and 2020
- Solid equity base with CHF 91.7 million
- Debt free

[1] Prior to the implementation of IFRS 15 the unrecognized revenue from collaboration agreements was labeled as deferred revenues; with the implementation of IFRS 15 in 2018 these amounts are now labeled as contract liabilities.

MOLECULAR partners

Accounting Revenues

In CHF million



Note: Rounding differences may occur

Highlights

- Reduced revenues from partners reflects Molecular Partners' strategy to invest and forward-integrate into proprietary assets
- CHF 49.3 million (USD 50 million) upfront fee from Amgen collected in January 2019 and recognized as revenues pro-rata from contract signing in Dec 2018 until Q3 2020
- CHF 10.4 million accounting revenues in 2018, thereof CHF 0.9 million pro-rata from Amgen upfront fee and CHF 9.4 million non-cash effective revenue recognitions from Allergan collaboration

MOLECULAR partners

Operating Expenses

in CHF million (incl. depreciation & amortization)



Note: Rounding differences may occur

Highlights

- Expense development in line with expectations
- Ongoing scale-up of R&D to accelerate pipeline growth; R&D share of total expenses remains constant at 80%
- Main cost drivers in 2018:
  - Investments in pre-clinical and clinical development of proprietary oncology assets (MP0250, MP0274, MP0310)
  - Personnel cost, reflecting ongoing build-out and growth of organization
  - Expenses include non CHF 5.2 million non-cash effective costs

MOLECULAR partners

Financial Guidance for Full-Year 2019

- Total expenses of CHF 70-80 million,
  of which around CHF 7 million non-cash effective costs
- Capital expenditures of ca. CHF 3 million
- No guidance on net cash flow;
  timelines and potential milestones payments with partnerships not disclosed
- Guidance subject to progress and changes of pipeline

MOLECULAR partners

Outlook 2019 & Beyond

DARPin® Engine: Our Differentiated Platform as Continuous Source of Novel Therapeutic Designs

DARPin® module selection



Opening novel Therapeutic Design Space



Multi-DARPin® product candidates

Selecting the «optimal» Therapeutic Design



Therapeutic Design matches its function

MOLECULAR partners

DARPin® Strategy in Oncology

Antigen-presenting cells, T cells

PRIME & ACTIVATE

Localized Immune Modulators

T cells

ENGAGE

Cytotoxic Immune Cells

Tumor cells

DIRECT KILL

Direct Tumor Cell Killing

Tumor / Stromal cell interactions

MODULATE

Tumor Microenvironment Modulators

T cells

UNBLOCK

Checkpoint Approaches



MOLECULAR partners

Investment Case

- **DARPin® Engine and Research:** Source for candidates with novel therapeutic designs
- Advanced and **balanced DARPin® Portfolio**
  - **Abicipar** in pivotal trial with potential to be **first fixed 12-week anti VEGF** in nAMD with Allergan's targeted launch approaching
  - Clinical oncology pipeline with **MP0250 in phase 2** and **MP0274 in phase 1**
- Organizational focus on product innovation and **company growth**
- **Partnerships** to accelerate development of DARPin® candidates
- **Well financed** and on-track towards steady income with Allergan's expected Abicipar launch in 2020

Accelerating Progress in 2019 and Beyond

	2019	2020
Abicipar	▪ BLA filing planned (H1) ▪ DME: P3 start ▪ MAPLE: results of further optimized material (H1)	▪ nAMD Launch
MP0250	▪ Additional data: ongoing P2 MM trial ▪ Start of P2 PI and IMiD-combo trial in MM ▪ Interim results from P2 NSCLC trial	▪ Interim P2 data: PI-combo trial ▪ Interim P2 data: IMiD-combo trial
MP0274	▪ First safety & interim efficacy data	
MP0310	▪ FIH with MP0310 (mono therapy)	▪ MP0310 combination trials
Research	▪ Advance DARPin® candidates ▪ Establish novel therapeutic designs	
Capital	Funding into H2 2020 (excl. any abicipar related proceeds)	

MOLECULAR partners

MOLECULAR partners

Thank you

MOLECULAR partners

Questions?

Appendix

Shareholder Structure

Shareholder structure as of December 31, 2018



- Pre-IPO investors (4 VC's)
- Management, Board, Founders
- Others

* According to SIX Swiss Exchange Filings

Highlights

- VC holdings halved vs. end 2016 to 23%
- Listed on SIX Swiss Exchange (SIX: MOLN)
- Included in key indices: SPI, SPI Extra, SXI Life Sciences and SXI Bio+Medtech
- 21,228,593 shares outstanding
- Ca. CHF 405 million market cap. as of Dec. 31, 2018
- No lock-up restrictions in place
- Formal free float as per SIX definition: 84%

Income Statement

(CHF million)	***FY 2017***	*FY 2017*	*FY 2016*	*FY 2015*	*FY 2014*
Revenues	**10.4**	20.0	23.0	29.1	26.6
R&D expenses[1]	**(38.2)**	(37.4)	(35.2)	(25.0)	(19.8)
G&A expenses[2]	**(9.6)**	(8.4)	(7.3)	(6.3)	(5.0)
Operating result	**(37.4)**	(25.8)	(19.5)	(2.2)	1.8
Net financial result	**0.4**	0.4	0.9	2.1	(4.1)[3]
Net result	**(37.0)**	(25.4)	(18.6)	(0.1)	(2.3)

[1] Thereof non-cash costs of CHF 2.3m in FY2014, CHF 3.7m in FY2015, CHF 3.4m in FY2016, CHF 2.9m in FY2017 and CHF 3.2 m in FY 2018
[2] Thereof non-cash costs of CHF 1.1m in FY2014, CHF 1.6m in FY2015, CHF 1.3m in FY2016, CHF 2.1m in FY2017 and CHF 2.1m in FY 2018
[3] Including CHF 7.1m IPO costs
Note: Rounding differences may occur

Cash Flow Statement

(CHF million)	***FY 2018***	*FY 2017*	*FY 2016*	*FY 2015*	*FY 2014*
Net cash from / (used in) operations	**(42.5)**	(40.0)	(35.4)	26.5	(11.3)
Net cash from / (used in) investing	**9.6**[5]	20.9[4]	(11.3)[3]	(20.7)[2]	(0.2)
Net cash from / (used in) financing	**0.4**	0.8	0.4	0.2	101.2[1]
Exchange gain / (loss) on cash	**0.1**	(0.1)	0.6	1.0	2.6
Net cash increase / (decrease)	**(32.4)**	(18.4)	(45.7)	7.0	92.3
Cash balance at year end	**99.0**	141.1[4]	180.2[3]	215.4[2]	188.4

[1] Net increase of equity of CHF 100.9m due to IPO
[2] Includes CHF 20.0 million short-term time deposits
[3] includes CHF 10.5 million increase in short-term time deposits, CHF 30.5 million short-term time deposits at yearend
[4] includes CHF 20.7 million decrease in short-term time deposits, CHF 9.8 million short-term time deposits at yearend
[5] includes CHF 9.7 million decrease in short-term time deposits
Note: Rounding differences may occur

Balance Sheet

(CHF million)	***FY 2018***	*FY 2017*	*FY 2016*	*FY 2015*	*FY 2014*
Non-current assets	**1.8**	1.9	2.5	2.5	2.1
Other current assets[1]	**54.4**[7]	1.4	1.4	1.5	3.5
Cash balance	**99.0**	141.1[6]	180.2[5]	215.4[4]	188.4
Shareholders' equity	**91.7**	116.7	135.8	151.8	148.5
Non-current liabilities[2]	**26.6**	13.6	32.5	41.2	23.4
Current liabilities[3]	**36.9**	14.1	15.8	26.4	22.1

[1] Prepayments and other assets, trade and other receivables
[2] Thereof deferred revenues / contract liabilities of CHF 20.4m in FY2014, CHF 37.0m in FY2015, CHF 26.8m in FY2016, CHF 9.5m in FY2017 and CHF 20.9 in FY 2018
[3] Thereof deferred revenues / contract liabilities of CHF 18.5m in FY2014, CHF 22.2m in FY2015, CHF 10.5m in FY2016, CHF 8.9m in FY2017 and CHF 27.8 in 2018
[4] Includes CHF 20.0 million short-term time deposits
[5] Includes CHF 30.5 million short-term time deposits
[6] Includes CHF 9.8 million short-term time deposits
[7] Includes CHF 49.3 million as receivable on Amgen, paid in January 2019
Note: Rounding differences may occur

Molecular Partners AG
Wagistrasse 14
8952 Zürich-Schlieren
Switzerland
www.molecularpartners.com
T +41 44 755 77 00

IR Agenda

March 15, 2019	Expected Publication of Annual Report 2018
April 16, 2019	Annual General Meeting
May 9, 2019	Interim Management Statement Q1 2019